864359-18-2

Upstream product

• 873-75-6 4-bromobenzenemethanol 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 206446-48-2 tert-butyl 4-[4-(ethoxycarbonyl)phenyl]piperidine-1-carboxylate 
• 149353-75-3 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzoic acid 
• 856684-33-8 tert-butyl 4-(4-formylphenyl)-1,2,3,6-tetrahydropyridine-1-carboxylate 

Downstream Products

• 1093190-55-6 4-(4-morpholin-4-ylmethylphenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1240969-39-4 tert-Butyl 4-(4-((2-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)phenoxy)methyl)phenyl)piperidine-1-carboxylate 
• 1240969-73-6 tert-Butyl 4-{4-[(2-[6-{4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-2-yl}-6-fluorophenoxy)methyl]phenyl}piperidine-1-carboxylate 
• 1240970-19-7 tert-Butyl 4-(4-((2-(6-(5-amino-4-(ethoxycarbonyl)-1-pyrazol-1-yl)pyridin-2-yl)phenoxy)methyl)phenyl)piperidine-1-carboxylate 
• 732275-93-3 4-(4-formylphenyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 
• 1093190-63-6 (2S,3R)-3-hydroxy-2-(4-(4-(4-morpholin-4-ylmethylphenyl)piperidin-1-yl)benzoylamino)butyric acid methyl ester 
• 1093190-59-0 4-(4-(4-morrpholin-4-ylmethylphenyl)piperidin-1-yl)benzoic acid methyl ester 
• 1240967-48-9 1-(6-(2-((4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 

Relevant academic research and scientific papers

3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

TARGETED PROTEIN DEGRADATION

This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

ETHER COMPOUNDS AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis and/or cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions of these compounds are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions are also provided.

Practical synthesis of pharmaceutically relevant molecules enriched in sp3 character

The expedient synthesis of compounds enriched in sp3 character is key goal in modern drug discovery. Herein, we report how a single pot Suzuki-Miyaura-hydrogenation can be used to furnish lead and fragment-like products in good to excellent yields. The approach has been successfully applied in formats amenable to parallel synthesis, in an asymmetric sense, and in the preparation of molecules with annotated biological activity.

Soluble Guanylate Cyclase Activators

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Immunosuppressant Compounds and Compositions

The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention relates to a medicament comprising the compound of formula (I) wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof The compound of the present invention is useful for the pr